Press release
Hereditary Angioedema (HAE) Market Forecast 2024-2034
Hereditary Angioedema (HAE) Market
The Hereditary Angioedema (HAE) Market is expanding rapidly due to increased diagnosis rates, patient awareness, and the availability of advanced on-demand and prophylactic therapies.
HAE is a rare, genetic disorder characterized by recurrent episodes of severe swelling affecting the skin, gastrointestinal tract, and upper airways, often caused by C1-inhibitor deficiency or dysfunction. Rising adoption of genetic testing, improved treatment guidelines, and the introduction of next-generation monoclonal antibodies and oral kallikrein inhibitors are transforming the therapeutic landscape. Strong research activity and supportive rare disease policies continue to drive market momentum globally.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71655
Market Dynamics
Drivers
• Rising global awareness and earlier diagnosis of rare immunologic disorders
• Increased availability of C1-inhibitor replacement therapies and kallikrein inhibitors
• Growing use of prophylactic therapies reducing attack frequency
• Strong R&D investment in monoclonal antibodies and gene therapy approaches
• Government support for rare disease registries and patient tracking
Restraints
• High cost of long-term HAE therapy, especially biologics
• Limited specialist availability for rare immunologic disorders
• Underdiagnosis in emerging regions due to lack of awareness
• Variations in disease presentation leading to delayed treatment
Opportunities
• Development of oral small-molecule kallikrein inhibitors for convenient prophylaxis
• Emerging gene therapy and RNA-based platforms targeting HAE at the genetic level
• Expansion of home-care and self-administration treatment models
• AI-supported predictive tools for attack forecasting and personalized care
• Growing investment from biopharma companies encouraged by orphan drug incentives
Trend Analysis
• Increasing use of long-acting monoclonal antibodies for preventive treatment
• Rise of oral, once-daily prophylactic therapies improving patient quality of life
• Enhanced genetic screening programs for family members
• Expansion of real-world evidence (RWE) studies evaluating treatment durability
• Digital apps and wearables enabling attack tracking and remote monitoring
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71655/hereditary-angioedema-market
Segment Analysis
By Treatment Type
• C1-inhibitor replacement therapy (IV and SC)
• Kallikrein inhibitors (IV, SC, and oral)
• Monoclonal antibodies (long-term prophylaxis)
• On-demand treatments for acute attacks
• Emerging gene therapies (pipeline)
By Attack Type
• Peripheral swelling attacks
• Abdominal attacks
• Laryngeal attacks (life-threatening)
• Multi-site attacks
By End User
• Hospitals
• Specialty immunology & allergy clinics
• Home-care settings
• Research institutions
Regional Analysis
• North America leads the market due to strong adoption of biologics, high awareness, and extensive access to prophylactic therapies.
• Europe shows strong performance with structured rare-disease frameworks and widespread availability of advanced HAE drugs.
• Asia Pacific is a rapidly expanding market driven by increasing diagnostic capabilities and healthcare investment.
• Latin America, Middle East & Africa are emerging regions with growing awareness and gradual improvements in immunology care.
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71655
Competitive Landscape - Key Companies
• Takeda Pharmaceuticals
• CSL Behring
• BioCryst Pharmaceuticals
• Pharming Group
• Ionis Pharmaceuticals
• Attune Pharmaceuticals
• KalVista Pharmaceuticals
• Regeneron Pharmaceuticals
• Sanofi
• Roche
• Thermo Fisher Scientific (diagnostic technologies)
• Invitae (genetic testing)
Recent Developments
• Approval and increased uptake of oral prophylactic medications
• New monoclonal antibodies demonstrating sustained attack reduction
• Clinical progress in RNA-based and gene therapy approaches
• Expansion of home-infusion and self-injection models globally
• Improved diagnostic panels for early and family screening
This report is also available in the following languages : Japanese (遺伝性血管性浮腫市場), Korean (유전성 혈관부종 시장), Chinese (遗传性血管性水肿市场), French (Marché de l'angio-œdème héréditaire), German (Markt für hereditäres Angioödem), and Italian (Mercato dell'angioedema ereditario), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71655
Our More Reports:
IgA Nephropathy Market
https://exactitudeconsultancy.com/reports/71530/iga-nephropathy-market
Rheumatoid Arthritis Market
https://exactitudeconsultancy.com/reports/71532/rheumatoid-arthritis-market
Febrile Neutropenia Market
https://exactitudeconsultancy.com/reports/71534/febrile-neutropenia-market
Hepatic Impairment Market
https://exactitudeconsultancy.com/reports/71536/hepatic-impairment-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hereditary Angioedema (HAE) Market Forecast 2024-2034 here
News-ID: 4309687 • Views: …
More Releases from Exactitude Consultancy
Immune Thrombocytopenia (ITP) Market is projected to reach USD 4.89 billion by 2 …
The global Immune Thrombocytopenia (ITP) Market was valued at USD 2.46 billion in 2024 and is projected to reach USD 4.89 billion by 2034, growing at a CAGR of 7.1% during the forecast period (2025-2034). Market growth is fueled by advancements in targeted therapies, increasing diagnosis rates, growing awareness among physicians and patients, and expanding use of thrombopoietin receptor agonists (TPO-RAs) for chronic ITP.
Download Full PDF Sample Copy of Market…
Fragile X Syndrome (FXS) Market Expected to Experience Major Growth by 2034
Market Overview
The Fragile X Syndrome (FXS) Market is progressing steadily as advancements in genetic diagnostics, early childhood screening, and targeted therapeutic research drive demand for improved clinical management of this inherited neurodevelopmental disorder.
FXS results from a mutation in the FMR1 gene, leading to reduced or absent production of the FMRP protein, which is essential for normal synaptic development. Rising global awareness of developmental delays and autism spectrum-related symptoms, broader…
Venous Leg Ulcer (VLU) Market is projected to reach USD 5.31 billion by 2034
The global Venous Leg Ulcer (VLU) Market was valued at USD 2.89 billion in 2024 and is projected to reach USD 5.31 billion by 2034, growing at a CAGR of 6.3% during the forecast period (2025-2034). Growth is driven by the increasing prevalence of chronic venous insufficiency (CVI), rising geriatric population, growing incidence of obesity and diabetes, and expanding adoption of advanced wound care products designed for chronic, non-healing ulcers.
Download…
Duchenne Muscular Dystrophy (DMD) Market Growth in 2034
Market Overview
The Duchenne Muscular Dystrophy (DMD) Market is expanding rapidly as advances in genetic medicine, exon-skipping therapies, gene therapy platforms, and improved diagnostic capabilities reshape treatment options for this severe, progressive neuromuscular disorder.
DMD is caused by mutations in the dystrophin gene, leading to muscle degeneration beginning in early childhood. Growing awareness among clinicians and caregivers, widespread adoption of next-generation sequencing (NGS), and increasing availability of disease-modifying therapies have significantly strengthened…
More Releases for HAE
Hereditary Angioedema (HAE) market is expected to reach USD 4.2 billion by 2034
Hereditary Angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent swelling episodes in the skin, gastrointestinal tract, and airways. Caused by C1 inhibitor deficiency or dysfunction, HAE affects an estimated 1 in 50,000 people worldwide. Though once underdiagnosed and undertreated, awareness and therapeutic innovation have dramatically changed the disease landscape in recent years.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71655
The HAE market has witnessed a…
Hereditary Angioedema (HAE) Treatment Market Analysis Report 2022 - 2030
Acumen Research and Consulting has announced the addition of the "Hereditary Angioedema (HAE) Treatment Market" report to their offering.
The Hereditary Angioedema (HAE) Treatment Market Report 2030 is an in depth study analyzing the current state of the Hereditary Angioedema (HAE) Treatment Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Hereditary Angioedema (HAE) Treatment Market provides analysis…
HAE MEMBERSHIP GIVES DIAMOND BLADES BUSINESS A CUTTING EDGE
The UK construction industry brings in billions of pounds of new work every month*. The sector relies on tool and equipment hire companies to deliver the kit needed to undertake these projects, so how can suppliers gain a competitive edge in such an important marketplace?
Established in 2003, Mexco has already grown from its Cornwall base to become one of the UK and Ireland’s largest privately-owned suppliers of diamond blades, core…
MENTAL HEALTH IN THE SPOTLIGHT AT HAE EHA CONFERENCE
Members, non-members and exhibitors attending HAE EHA’s annual conference at Holywell Park in Loughborough were given an ideal opportunity to assess and improve their strategies for dealing with mental health in the workplace by expert speakers on this growing issue.
It is estimated mental health problems blight one in four of the UK population (http://www.hse.gov.uk/stress/mental-health.htm), a figure replicated last year in the construction industry according to a survey by Construction News’…
Hereditary Angioedema (HAE) - Pipeline Review, Trends, and Forecast Report 2017
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Hereditary Angioedema (HAE) - Pipeline Review, H1 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196650
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) -…
Hereditary Angioedema (HAE) Market Research Report | Forecast up to 2024
Global Hereditary Angioedema (HAE) Market: Overview
Hereditary angioedema (HAE) is a rare inherited disease, which leads to repeated episodes of swelling beneath the surface of the skin. Hereditary angioedema is confined to the face, tongue, feet, legs, hands and arms. However, it sometimes leads to swelling in airways such as trachea, larynx or intestinal tract may prove out to be fatal.
For the treatment of hereditary angioedema, currently there are no medications…
